Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Nu Holdings Ltd (NU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Nu Holdings Ltd — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $13.52 (market cap $5.85B), while Nu Holdings Ltd trades at $15.44 (market cap $75.26B). The key difference: Nu Holdings Ltd is far larger — about 12.9× Iovance Biotherapeutics Inc. Common Stock's market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, Nu Holdings Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Nu Holdings Ltd for 53 Days on average.
| IOVA | NU | |
|---|---|---|
Market Cap | $5.85B | $75.26B |
Volume | 14,517,176 | 82,363,718 |
Sector | Health | Financials |
52-Week High | $14.82 | $18.76 |
52-Week Low | $1.81 | $11.60 |
Typical Hold Time | 0 Days | 53 Days |
Enterprise Value | $5.78B | $97.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NU Holdings trades at $15.38, down 1.79% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with revenue growing from $3.0B in 2022 to $10.6B in 2025 and net income reaching $2.9B. Recent news highlights market volatility around potential acquisition rumors, though the company has denied pursuing a Monzo deal.
The outlook remains positive with analyst consensus favoring Buy ratings (56.52%) and a $16.53 price target suggesting 7.5% upside. Key risks include credit quality concerns from expanding lending operations and high customer concentration. Revenue growth and profitability trends support continued investor interest despite recent earnings misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Nu Holdings Ltd
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.
Read more on NU →
